Therapy Areas: Oncology
FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
15 October 2021 - - The US Food and Drug Administration has approved Keytruda, US-based pharmaceutical company Merck's (NYSE: MRK) anti-PD-1 therapy, in combination with chemotherapy, with or wit...
First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors
15 October 2021 - - The first patient has been dosed in US-based cancer immunotherapy company Immune-Onc Therapeutics, Inc's first-in-human clinical trial of IO-108, a novel antagonist antibody t...
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
15 October 2021 - - US-based life science company Agilent Technologies Inc's (NYSE: A) Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early b...
Abalos Therapeutics Completes series A Extension Bringing Total Raised to EUR 43m
15 October 2021 - - Germany-based Abalos Therapeutics has extended its series A funding round bringing the total raised in this round to EUR 43m (USD 50m), the company said.

The exte...
FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
15 October 2021 - - The US Food and Drug Administration has approved Keytruda, US-based pharmaceutical company Merck's (NYSE: MRK) anti-PD-1 therapy, in combination with chemotherapy, with or wit...
Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies
15 October 2021 - - US-based clinical-stage company Tizona Therapeutics, Inc's lead investigational therapy, TTX-080, a novel antibody targeting HLA-G, has advanced to Phase 1b, the company said....
Related Headlines

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's Lymphoma

Cantargia receives positive EMA opinion for orphan designation of nadunolimab in pancreatic cancer

Eli Lilly's Verzenio(R) (abemaciclib) and endocrine therapy combination gains US FDA breast cancer treatment approval

Eli Lilly wins FDA approval of Verzenio for treatment of HR+ HER2- high risk early breast cancer

Lucid Diagnostics prices IPO at USD14.00 per share

Kiromic BioPharma Forges Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers

First Patient Dosed in Phase 1 Clinical Study of RPTR-168 (PRIME IL-12) for Relapsed or Refractory HPV-16-Positive Tumors

BeiGene Announces Brukinsa (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia

DarwinHealth and Prelude Therapeutics enter into scientific research collaboration

Quanterix Granted Breakthrough Device Designation from US FDA for Blood-Based pTau-181 Assay for Alzheimer's Disease

Parse Biosciences Extends RNA-Seq Kit Reach to Australia and New Zealand through Decode Sciences Agreement

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma

Sirtex performs first procedure of selective internal radiation therapy using SIR-Spheres Y-90 resin microspheres

Tezepelumab Granted Orphan Drug Designation in the US for Eosinophilic Esophagitis

OncoNano Medicine Presents Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology and Immunotherapy